TY - CHAP M1 - Book, Section TI - Neuropathies Associated with Malignancy A1 - Amato, Anthony A. A1 - Russell, James A. Y1 - 2015 N1 - T2 - Neuromuscular Disorders, 2e AB - Patients with malignancy can develop peripheral neuropathies as the result of (1) a direct effect of the cancer by invasion or compression of the nerves, (2) a remote or paraneoplastic effect including vasculitis, (3) a direct toxic effect of treatment, or (4) an alteration of immune status caused by immunosuppression (Table 19-1).1,2 It is difficult to estimate the frequency of polyneuropathy in patients with cancer because it is dependent on a number of factors including the type, stage, and location of the malignancy, as well as confounding variables such as malnutrition, the toxic effects of therapy, and the background incidence of neuropathy in this frequently older population. Nevertheless, some series indicate that 1.7–5.5% of patients with cancer have clinical symptoms or signs of a peripheral neuropathy, while neurophysiologic testing (quantitative sensory testing and nerve conduction studies [NCS]) demonstrates evidence of peripheral neuropathy in as many as 30–40% of patients with cancer.3 The most common associated malignancy is lung cancer, but neuropathies also complicate carcinoma of the breast, ovaries, stomach, colon, rectum, and other organs including the lymphoproliferative system. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - neurology.mhmedical.com/content.aspx?aid=1115659172 ER -